{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    4,
    5,
    6,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20
  ],
  "modelUsed": "gemini-3-flash-preview",
  "objectivesEndpoints": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients (patient population prospectively defined as noted in Section 7.5.1) with aRCC.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary PFS Objective (Unselected)",
        "text": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS in the first-line treatment of patients with aRCC unselected for PD-L1 expression.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary OS Objective (Unselected)",
        "text": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging OS in the first-line treatment of patients with aRCC unselected for PD-L1 expression.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Other Efficacy Measures",
        "text": "To evaluate other measures of efficacy of avelumab in combination with axitinib and sunitinib monotherapy in the first-line treatment of aRCC patients.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Next-line Therapy Objective",
        "text": "To evaluate progression-free survival on next-line of therapy (PFS2).",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Safety Objective",
        "text": "To evaluate the overall safety profile of avelumab in combination with axitinib and sunitinib monotherapy in the first-line treatment of aRCC patients.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Toxicity Discontinuation Objective",
        "text": "To evaluate the time to treatment discontinuation/failure due to toxicity.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Toxicity Proportion Objective",
        "text": "To evaluate the proportion of patients who discontinued treatment due to toxicity.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Pharmacokinetics Objective",
        "text": "To evaluate the population pharmacokinetics of avelumab and axitinib when administered in combination.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Biomarker Objective",
        "text": "To evaluate candidate predictive biomarkers in pre-treatment tumor tissue that may aid in the identification of a patient subpopulation most likely to benefit from treatment with avelumab in combination with axitinib and sunitinib monotherapy.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12",
          "ep_13"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Immunogenicity Objective",
        "text": "To assess the immunogenicity of avelumab when combined with axitinib.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_14"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Patient-Reported Outcomes Objective",
        "text": "To evaluate the effects of avelumab in combination with axitinib and sunitinib monotherapy on patient-reported outcomes.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_15"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary PFS (PD-L1+)",
        "text": "Progression-Free Survival (PFS) based on Blinded Independent Central Review (BICR) assessment per RECIST v.1.1 for PD-L1 positive patients (patient population prospectively defined as noted in Section 7.5.1).",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Primary OS (PD-L1+)",
        "text": "Overall Survival (OS) for PD-L1 positive patients (patient population prospectively defined as noted in Section 7.5.1).",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary PFS (Unselected)",
        "text": "PFS by BICR assessment per RECIST v.1.1 for patients unselected for PD-L1 expression.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary OS (Unselected)",
        "text": "OS for patients unselected for PD-L1 expression.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Tumor Response Endpoints",
        "text": "Objective Response (OR), Disease Control (DC), Time to Tumor Response (TTR) and Duration of Response (DR) based on BICR assessment and based on Investigator assessment, per RECIST v.1.1.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Investigator PFS",
        "text": "Progression-Free Survival (PFS) based on Investigator assessment per RECIST v.1.1.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "PFS2 Endpoint",
        "text": "Progression-Free Survival on next-line therapy (PFS2).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Safety Endpoints",
        "text": "Adverse events (AEs) and laboratory abnormalities as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 (Appendix 6); vital signs (blood pressure, pulse rate).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_9",
        "name": "Time to Discontinuation",
        "text": "Time to treatment discontinuation/failure due to toxicity.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Tolerability"
      },
      {
        "id": "ep_10",
        "name": "Treatment Discontinuation",
        "text": "Treatment discontinuation due to toxicity.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Tolerability"
      },
      {
        "id": "ep_11",
        "name": "PK Parameters",
        "text": "PK parameters including trough concentrations (Ctrough) of avelumab and trough concentrations (Ctrough) and maximum concentrations (Cmax) of axitinib.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_12",
        "name": "Biomarker Status",
        "text": "Tumor tissue biomarker status (ie, positive or negative; based on, for example, PD-L1 expression and/or quantitation of tumor infiltrating CD8+ T lymphocytes as assessed by immunohistochemistry [IHC]).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_13",
        "name": "Biomarker Subgroup Outcomes",
        "text": "Measures of clinical outcome (PFS, OS, OR, DC, TTR, and DR) in biomarker-positive and biomarker-negative subgroups.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_14",
        "name": "Immunogenicity Endpoint",
        "text": "Anti-drug antibodies (ADAs; nAbs) of avelumab when in combination with axitinib.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_15",
        "name": "PRO Endpoints",
        "text": "Patient-Reported Outcomes (PRO): FACT-Kidney Symptom Index (FKSI-19), EuroQol 5-Dimension (EQ 5D).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary PFS Estimand (PD-L1+)",
        "populationSummary": "PD-L1 positive patients with advanced renal cell carcinoma (Full Analysis Set) Summary measure: Hazard Ratio (HR) from stratified log-rank test.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation due to toxicity",
            "text": "Patient stops study treatment due to unacceptable toxicity",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to any cause prior to progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Subsequent anti-cancer therapy",
            "text": "Initiation of new anti-cancer therapy prior to progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Avelumab 10 mg/kg IV Q2W + Axitinib 5 mg PO BID vs Sunitinib 50 mg PO QD (4/2 schedule)",
        "analysisPopulation": "PD-L1 positive patients with advanced renal cell carcinoma (Full Analysis Set)",
        "variableOfInterest": "Progression-Free Survival (PFS) based on BICR assessment per RECIST v.1.1",
        "summaryMeasure": "Hazard Ratio (HR) from stratified log-rank test"
      },
      {
        "id": "est_2",
        "name": "Primary OS Estimand (PD-L1+)",
        "populationSummary": "PD-L1 positive patients with advanced renal cell carcinoma (Full Analysis Set) Summary measure: Hazard Ratio (HR) from stratified log-rank test.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment for any reason",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Avelumab 10 mg/kg IV Q2W + Axitinib 5 mg PO BID vs Sunitinib 50 mg PO QD (4/2 schedule)",
        "analysisPopulation": "PD-L1 positive patients with advanced renal cell carcinoma (Full Analysis Set)",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio (HR) from stratified log-rank test"
      },
      {
        "id": "est_3",
        "name": "Secondary PFS Estimand (Unselected)",
        "populationSummary": "All randomized patients (All Comers) with advanced renal cell carcinoma Summary measure: Hazard Ratio (HR) from stratified log-rank test.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Death",
            "text": "Death due to any cause prior to progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Avelumab 10 mg/kg IV Q2W + Axitinib 5 mg PO BID vs Sunitinib 50 mg PO QD (4/2 schedule)",
        "analysisPopulation": "All randomized patients (All Comers) with advanced renal cell carcinoma",
        "variableOfInterest": "Progression-Free Survival (PFS) based on BICR assessment per RECIST v.1.1",
        "summaryMeasure": "Hazard Ratio (HR) from stratified log-rank test"
      },
      {
        "id": "est_4",
        "name": "Secondary OS Estimand (Unselected)",
        "populationSummary": "All randomized patients (All Comers) with advanced renal cell carcinoma Summary measure: Hazard Ratio (HR) from stratified log-rank test.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment for any reason",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Avelumab 10 mg/kg IV Q2W + Axitinib 5 mg PO BID vs Sunitinib 50 mg PO QD (4/2 schedule)",
        "analysisPopulation": "All randomized patients (All Comers) with advanced renal cell carcinoma",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio (HR) from stratified log-rank test"
      }
    ],
    "summary": {
      "primaryObjectives": 1,
      "secondaryObjectives": 11,
      "exploratoryObjectives": 0,
      "totalEndpoints": 15,
      "totalEstimands": 4
    }
  },
  "rawResponse": {
    "objectives": [
      {
        "id": "obj_1",
        "name": "Primary Efficacy Objective",
        "text": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS or OS in the first-line treatment of PD-L1 positive patients (patient population prospectively defined as noted in Section 7.5.1) with aRCC.",
        "level": {
          "code": "C85826",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Primary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_1",
          "ep_2"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_2",
        "name": "Secondary PFS Objective (Unselected)",
        "text": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging PFS in the first-line treatment of patients with aRCC unselected for PD-L1 expression.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_3"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_3",
        "name": "Secondary OS Objective (Unselected)",
        "text": "To demonstrate that avelumab in combination with axitinib is superior to sunitinib monotherapy in prolonging OS in the first-line treatment of patients with aRCC unselected for PD-L1 expression.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_4"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_4",
        "name": "Other Efficacy Measures",
        "text": "To evaluate other measures of efficacy of avelumab in combination with axitinib and sunitinib monotherapy in the first-line treatment of aRCC patients.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_5",
          "ep_6"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_5",
        "name": "Next-line Therapy Objective",
        "text": "To evaluate progression-free survival on next-line of therapy (PFS2).",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_7"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_6",
        "name": "Safety Objective",
        "text": "To evaluate the overall safety profile of avelumab in combination with axitinib and sunitinib monotherapy in the first-line treatment of aRCC patients.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_8"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_7",
        "name": "Toxicity Discontinuation Objective",
        "text": "To evaluate the time to treatment discontinuation/failure due to toxicity.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_9"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_8",
        "name": "Toxicity Proportion Objective",
        "text": "To evaluate the proportion of patients who discontinued treatment due to toxicity.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_10"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_9",
        "name": "Pharmacokinetics Objective",
        "text": "To evaluate the population pharmacokinetics of avelumab and axitinib when administered in combination.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_11"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_10",
        "name": "Biomarker Objective",
        "text": "To evaluate candidate predictive biomarkers in pre-treatment tumor tissue that may aid in the identification of a patient subpopulation most likely to benefit from treatment with avelumab in combination with axitinib and sunitinib monotherapy.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_12",
          "ep_13"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_11",
        "name": "Immunogenicity Objective",
        "text": "To assess the immunogenicity of avelumab when combined with axitinib.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_14"
        ],
        "instanceType": "Objective"
      },
      {
        "id": "obj_12",
        "name": "Patient-Reported Outcomes Objective",
        "text": "To evaluate the effects of avelumab in combination with axitinib and sunitinib monotherapy on patient-reported outcomes.",
        "level": {
          "code": "C85827",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Trial Secondary Objective",
          "instanceType": "Code"
        },
        "endpointIds": [
          "ep_15"
        ],
        "instanceType": "Objective"
      }
    ],
    "endpoints": [
      {
        "id": "ep_1",
        "name": "Primary PFS (PD-L1+)",
        "text": "Progression-Free Survival (PFS) based on Blinded Independent Central Review (BICR) assessment per RECIST v.1.1 for PD-L1 positive patients (patient population prospectively defined as noted in Section 7.5.1).",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_2",
        "name": "Primary OS (PD-L1+)",
        "text": "Overall Survival (OS) for PD-L1 positive patients (patient population prospectively defined as noted in Section 7.5.1).",
        "level": {
          "code": "C98772",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Primary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_3",
        "name": "Secondary PFS (Unselected)",
        "text": "PFS by BICR assessment per RECIST v.1.1 for patients unselected for PD-L1 expression.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_4",
        "name": "Secondary OS (Unselected)",
        "text": "OS for patients unselected for PD-L1 expression.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_5",
        "name": "Tumor Response Endpoints",
        "text": "Objective Response (OR), Disease Control (DC), Time to Tumor Response (TTR) and Duration of Response (DR) based on BICR assessment and based on Investigator assessment, per RECIST v.1.1.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_6",
        "name": "Investigator PFS",
        "text": "Progression-Free Survival (PFS) based on Investigator assessment per RECIST v.1.1.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_7",
        "name": "PFS2 Endpoint",
        "text": "Progression-Free Survival on next-line therapy (PFS2).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Efficacy"
      },
      {
        "id": "ep_8",
        "name": "Safety Endpoints",
        "text": "Adverse events (AEs) and laboratory abnormalities as graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.03 (Appendix 6); vital signs (blood pressure, pulse rate).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Safety"
      },
      {
        "id": "ep_9",
        "name": "Time to Discontinuation",
        "text": "Time to treatment discontinuation/failure due to toxicity.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Tolerability"
      },
      {
        "id": "ep_10",
        "name": "Treatment Discontinuation",
        "text": "Treatment discontinuation due to toxicity.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Tolerability"
      },
      {
        "id": "ep_11",
        "name": "PK Parameters",
        "text": "PK parameters including trough concentrations (Ctrough) of avelumab and trough concentrations (Ctrough) and maximum concentrations (Cmax) of axitinib.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacokinetic"
      },
      {
        "id": "ep_12",
        "name": "Biomarker Status",
        "text": "Tumor tissue biomarker status (ie, positive or negative; based on, for example, PD-L1 expression and/or quantitation of tumor infiltrating CD8+ T lymphocytes as assessed by immunohistochemistry [IHC]).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_13",
        "name": "Biomarker Subgroup Outcomes",
        "text": "Measures of clinical outcome (PFS, OS, OR, DC, TTR, and DR) in biomarker-positive and biomarker-negative subgroups.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Biomarker"
      },
      {
        "id": "ep_14",
        "name": "Immunogenicity Endpoint",
        "text": "Anti-drug antibodies (ADAs; nAbs) of avelumab when in combination with axitinib.",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "Pharmacodynamic"
      },
      {
        "id": "ep_15",
        "name": "PRO Endpoints",
        "text": "Patient-Reported Outcomes (PRO): FACT-Kidney Symptom Index (FKSI-19), EuroQol 5-Dimension (EQ 5D).",
        "level": {
          "code": "C98781",
          "codeSystem": "http://www.cdisc.org",
          "codeSystemVersion": "2024-09-27",
          "decode": "Secondary Outcome Measure",
          "instanceType": "Code"
        },
        "instanceType": "Endpoint",
        "purpose": "QualityOfLife"
      }
    ],
    "estimands": [
      {
        "id": "est_1",
        "name": "Primary PFS Estimand (PD-L1+)",
        "populationSummary": "PD-L1 positive patients with advanced renal cell carcinoma (Full Analysis Set) Summary measure: Hazard Ratio (HR) from stratified log-rank test.",
        "analysisPopulationId": "est_1_pop",
        "variableOfInterestId": "ep_1",
        "interventionIds": [
          "est_1_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_1",
            "name": "Treatment discontinuation due to toxicity",
            "text": "Patient stops study treatment due to unacceptable toxicity",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_2",
            "name": "Death",
            "text": "Death due to any cause prior to progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          },
          {
            "id": "ice_3",
            "name": "Subsequent anti-cancer therapy",
            "text": "Initiation of new anti-cancer therapy prior to progression",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Avelumab 10 mg/kg IV Q2W + Axitinib 5 mg PO BID vs Sunitinib 50 mg PO QD (4/2 schedule)",
        "analysisPopulation": "PD-L1 positive patients with advanced renal cell carcinoma (Full Analysis Set)",
        "variableOfInterest": "Progression-Free Survival (PFS) based on BICR assessment per RECIST v.1.1",
        "summaryMeasure": "Hazard Ratio (HR) from stratified log-rank test"
      },
      {
        "id": "est_2",
        "name": "Primary OS Estimand (PD-L1+)",
        "populationSummary": "PD-L1 positive patients with advanced renal cell carcinoma (Full Analysis Set) Summary measure: Hazard Ratio (HR) from stratified log-rank test.",
        "analysisPopulationId": "est_2_pop",
        "variableOfInterestId": "ep_2",
        "interventionIds": [
          "est_2_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_4",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment for any reason",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Avelumab 10 mg/kg IV Q2W + Axitinib 5 mg PO BID vs Sunitinib 50 mg PO QD (4/2 schedule)",
        "analysisPopulation": "PD-L1 positive patients with advanced renal cell carcinoma (Full Analysis Set)",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio (HR) from stratified log-rank test"
      },
      {
        "id": "est_3",
        "name": "Secondary PFS Estimand (Unselected)",
        "populationSummary": "All randomized patients (All Comers) with advanced renal cell carcinoma Summary measure: Hazard Ratio (HR) from stratified log-rank test.",
        "analysisPopulationId": "est_3_pop",
        "variableOfInterestId": "ep_3",
        "interventionIds": [
          "est_3_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_5",
            "name": "Death",
            "text": "Death due to any cause prior to progression",
            "strategy": "Composite",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Avelumab 10 mg/kg IV Q2W + Axitinib 5 mg PO BID vs Sunitinib 50 mg PO QD (4/2 schedule)",
        "analysisPopulation": "All randomized patients (All Comers) with advanced renal cell carcinoma",
        "variableOfInterest": "Progression-Free Survival (PFS) based on BICR assessment per RECIST v.1.1",
        "summaryMeasure": "Hazard Ratio (HR) from stratified log-rank test"
      },
      {
        "id": "est_4",
        "name": "Secondary OS Estimand (Unselected)",
        "populationSummary": "All randomized patients (All Comers) with advanced renal cell carcinoma Summary measure: Hazard Ratio (HR) from stratified log-rank test.",
        "analysisPopulationId": "est_4_pop",
        "variableOfInterestId": "ep_4",
        "interventionIds": [
          "est_4_int"
        ],
        "intercurrentEvents": [
          {
            "id": "ice_6",
            "name": "Treatment discontinuation",
            "text": "Discontinuation of study treatment for any reason",
            "strategy": "Treatment Policy",
            "instanceType": "IntercurrentEvent"
          }
        ],
        "instanceType": "Estimand",
        "treatment": "Avelumab 10 mg/kg IV Q2W + Axitinib 5 mg PO BID vs Sunitinib 50 mg PO QD (4/2 schedule)",
        "analysisPopulation": "All randomized patients (All Comers) with advanced renal cell carcinoma",
        "variableOfInterest": "Overall Survival (OS)",
        "summaryMeasure": "Hazard Ratio (HR) from stratified log-rank test"
      }
    ]
  }
}